Gilead Sciences Gets Initial OK On $247M HIV Antitrust Deal

By Bonnie Eslinger · September 21, 2023, 9:34 PM EDT

A California federal judge on Thursday granted preliminary approval to Gilead's deal to pay the direct purchasers of its HIV medications $246.8 million to end claims the pharmaceutical company cut a...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

In re HIV Antitrust Litigation

Case Number

3:19-cv-02573

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

May 14, 2019